REPLICor to Present at the 3rd Annual Viral Hepatitis in Drug Discovery & Development World Summit
Laval, Quebec – February 28, 2007 -- REPLICor announced today that Dr. Andrew Vaillant, Chief Scientific Officer, will be presenting at the 3rd Annual Viral Hepatitis in Drug Discovery & Development World Summit (Boston, March 12-13, 2007). He will participate also to the panel discussion on “Novel agents for Hepatitis C: Issues and Prospects for Multi-Class Combination Therapies” together with four important pharmaceutical companies.
About REPLICor:
REPLICor is a biopharmaceutical company developing applications for its novel DNA-based technology platform. REPLICor’s technology is based on the discovery that oligonucleotides have sequence independent and size dependent activities as amphipathic polymers with multiple potential clinical applications.
REPLICor has demonstrated that its two lead compounds, REP 9 and REP 9C, have potent activity against hepatitis C (HCV), influenza and other enveloped viruses. They have also been shown to be well tolerated in multiple animal studies. REP 9 and REP 9C can readily be synthesized in large quantities in cGMP facilities. The company business strategy is to enter into alliances with major biopharmaceutical companies in order to further develop and market its products.
For more information:
Andrew Vaillant PhD, CSO
REPLICor Inc.
450-688-6068